JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: Effect on neuroinflammation and antioxidant defence

Diabetes, Obesity and Metabolism

Volumn 13, Issue 8, 2011, Pages 750-758

  Kumar, A ^a   Negi, G ^a   Sharma, S S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic neuropathy; Experimental pharmacology

Indexed keywords

ANTIOXIDANT; CYCLOOXYGENASE 2; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; JSH 23; MALONALDEHYDE; PROTEIN INHIBITOR; PROTEIN P50; STREPTOZOCIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; HUMAN; HYPERALGESIA; INHIBITION KINETICS; MALE; MOTOR NERVE CONDUCTION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PAIN; PAIN THRESHOLD; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; SCIATIC NERVE; WESTERN BLOTTING;

EID: 79959441139     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01402.x     Document Type: Article

References (53)

1. Zhao Y, Ye W, Boye KS, Holcombe JH, Hall JA, Swindle R. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy. J Diabetes Complications 2010; 24: 9-19.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
3. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120: 1-34.
4. Feldman EL. Diabetic neuropathy. Curr Drug Targets 2008; 9: 1-2.
5. Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord 2004; 5: 227-236.
6. Cameron NE, Cotter MA. Pro-inflammatory mechanism in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 2008; 9: 60-67.
7. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005; 20: 2601-2604.
8. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 2000; 80: 1101-1110.
9. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 2008; 9: 60-67.
10. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010; 58: 585-592.
11. Michalowska-Wender G, Adamcewicz G, Wender M. Impact of cytokines on the pathomechanism of diabetic and alcoholic neuropathies. Folia Neuropathol 2007; 45: 78-81.
12. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
13. Arias-Salvatierra D, Silbergeld EK, Acosta-Saavedra LC, Calderon-Aranda ES. Role of nitric oxide produced by iNOS through NF-kappaB pathway in migration of cerebellar granule neurons induced by lipopolysaccharide. Cell Signal 2011; 23: 425-435.
14. Shin HM, Kim MH, Kim BH et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 2004; 571: 50-54.
15. Sharma SS, Kumar A, Arora M, Kaundal RK. Neuroprotective potential of combination of resveratrol and 4-amino 1, 8 naphthalimide in experimental diabetic neuropathy: focus on functional, sensorimotor and biochemical changes. Free Radic Res 2009; 43: 400-408.
16. Sharma SS, Kumar A, Kaundal RK. Protective effects of 4-amino1, 8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci 2008; 82: 570-576.
17. Arora M, Kumar A, Kaundal RK, Sharma SS. Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimental diabetic neuropathy. Eur J Pharmacol 2008; 596: 77-83.
18. Takeuchi M, Low PA. Dynamic peripheral nerve metabolic and vascular responses to exsanguination. Am J Physiol 1987; 253: E349-353.
19. Rundquist I, Smith QR, Michel ME, Ask P, Oberg PA, Rapoport SI. Sciatic nerve blood flow measured by laser Doppler flowmetry and [14C]iodoantipyrine. Am J Physiol 1985; 248: H311-317.
20. Negi G, Kumar A, Sharma SS. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 391: 102-106.
21. Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 2011; 50: 124-131.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
23. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979; 582: 67-78.
24. Obrosova IG, Li F, Abatan OI et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004; 53: 711-720.
25. Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394: 360-365.
26. Obrosova IG, Drel VR, Oltman CL et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007; 293: E1645-1655.
27. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-628.
28. Little AA, Edwards JL, Feldman EL. Diabetic neuropathies. Pract Neurol 2007; 7: 82-92.
29. Wang Y, Schmeichel AM, Iida H, Schmelzer JD, Low PA. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci 2006; 247: 47-52.
30. Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia 2006; 49: 3085-3093.
31. Li F, Szabo C, Pacher P et al. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 2004; 47: 710-717.
32. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004; 47: 331-339.
33. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39: 1-16.
34. Andorfer B, Kieseier BC, Mathey E et al. Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. J Neuroimmunol 2001; 116: 226-232.
35. Kundu JK, Shin YK, Surh YJ. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kB and AP-1 as prime targets. Biochem Pharmacol 2006; 72: 1506-1515.
36. Pop-Busui R, Marinescu V, Van Huysen C et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 2002; 51: 2619-2628.
37. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-608.
38. Garcia Soriano F, Virag L, Jagtap P et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-113.
39. Guo G, Bhat NR. Hypoxia/reoxygenation differentially modulates NF-kappaB activation and iNOS expression in astrocytes and microglia. Antioxid Redox Signal 2006; 8: 911-918.
40. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
41. Chan CF, Sun WZ, Lin JK, Lin-Shiau SY. Activation of transcription factors of nuclear factor kappa B, activator protein-1 and octamer factors in hyperalgesia. Eur J Pharmacol 2000; 402: 61-68.
42. Ma W, Bisby MA. Increased activation of nuclear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. Brain Res 1998; 797: 243-254.
43. Berti-Mattera LN, Kern TS, Siegel RE, Nemet I, Mitchell R. Sulfasalazine blocks the development of tactile allodynia in diabetic rats. Diabetes 2008; 57: 2801-2808.
44. Ling JJ, Sun YJ, Zhu DY, Chen Q, Han X. Potential role of NO in modulation of COX-2 expression and PGE2 production in pancreatic beta-cells. Acta Biochim Biophys Sin (Shanghai) 2005; 37: 139-146.
45. Matsunaga A, Kawamoto M, Shiraishi S et al. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 2007; 554: 12-17.
46. Acharyya S, Villalta SA, Bakkar N et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007; 117: 889-901.
47. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
48. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1995; 92: 11294-11298.
49. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54(Suppl. 2): S114-124.
50. Medeiros R, Prediger RD, Passos GF et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 2007; 27: 5394-5404.
51. Liu GH, Qu J, Shen X. NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 2008; 1783: 713-727.
52. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal 2011; 13: 1649-1663.
53. Chen K, Gunter K, Maines MD. Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death. J Neurochem 2000; 75: 304-313.